Tokenization replaces direct identifiers—such as names, dates of birth, and social security numbers—with tokens that allow cross-dataset linkage without exposing raw PII. Three primary tokenization paradigms dominate:

Deterministic tokenization applies a consistent algorithm producing the same token for identical inputs, facilitating reproducible linkage across data sources. This method is highly effective for structured datasets with stable identifiers, enabling longitudinal patient tracking and outcome analyses vital for pharmacovigilance. However, deterministic tokens may be vulnerable to re-identification if underlying algorithms are reverse-engineered or keys compromised (Bernstam et al., 2023).

Referential tokenization’s scalability and accuracy have been demonstrated in real-world applications, such as the linkage of large payer and non-payer datasets, with linkage precision exceeding 99% in high-fidelity settings (D’Andrea et al., 2024). This level of performance facilitates comprehensive safety signal detection, benefit-risk assessment, and population health research essential to pharmacovigilance.

Note: The overlap with non-payer (open) claims data was approximately 90%, based on linkage to clearinghouse data representing >70 million lives. By contrast, overlap with payer-specific datasets was ∼40%, though with higher precision in capturing longitudinal medical claims.

Table 1 summarizes the three primary tokenization methods alongside their key advantages for pharmacovigilance and pharmacoepidemiology.

A robust tokenization workflow typically involves several key stages that ensure privacy preservation in pharmacovigilance as seen in Table 2:

Identification of Sensitive Data Elements: Initially, data custodians identify direct identifiers (e.g., patient names, medical record numbers, exact dates of birth) and quasi-identifiers (e.g., ZIP codes, gender) subject to privacy protection (Bernstam et al., 2023).

The adoption of tokenization is tightly linked to regulatory frameworks governing patient privacy and pharmacovigilance. The Health Insurance Portability and Accountability Act (HIPAA) in the United States, the General Data Protection Regulation (GDPR) in the European Union, and the European Health Data Space Regulation (EU 2025/327) collectively emphasize pseudonymization and de-identification as cornerstones for lawful data reuse in safety surveillance (European Parliament, 2025; European Data Protection Board, 2021; Office for Civil Rights, 2023).

Referential tokenization aligns with these frameworks by enabling deterministic linkage via pseudonymous tokens while preventing the exchange or exposure of PII. The EHDS explicitly endorses token-based data linkage for secondary use of health data across EU member states, contingent upon compliance with GDPR principles (European Commission, 2025). Such alignment facilitates multinational clinical trials and pharmacovigilance studies that require longitudinal datasets while respecting data sovereignty and patient rights.

Clinical trial and pharmacovigilance datasets are inherently dynamic, reflecting ongoing changes in patient health status, treatment responses, and personal circumstances (Li et al., 2024). Tokenization frameworks must account for this variability to preserve critical longitudinal information needed for personalized interventions and accurate safety assessments. Failure to accommodate these fluctuations risks oversimplifying patient trajectories, diminishing the clinical and scientific value of pharmacovigilance data. Overreliance on aggregated population-level data risks masking heterogeneity in treatment effects and adverse event profiles, which are essential considerations in pharmacovigilance and precision medicine (Abul-Husn and Kenny, 2019). Consequently, tokenization methodologies should maintain sufficient granularity to support nuanced, patient-centric pharmacovigilance analyses throughout the clinical research lifecycle.

Accurate linkage of tokenized data is fundamental in pharmacovigilance and health economic studies. Over-linking, when unrelated patient records are mistakenly connected, can introduce confounding bias by falsely aggregating clinical events, exposures, or outcomes across distinct individuals. This misattribution may distort incidence rates, mask true safety signals, or generate spurious associations, ultimately compromising the validity of pharmacovigilance and real-world evidence analyses (Velummailum et al., 2023). Conversely, under-linking—failure to match related records—results in incomplete patient profiles and potential missed adverse drug reactions or treatment outcomes. Referential tokenization employs advanced matching algorithms supported by “golden records” or trusted data sources to mitigate these risks, enhancing the precision of pharmacovigilance cross-dataset linkage and minimizing both false positives and false negatives (Dunne, 2023).

Tokenization’s effectiveness depends heavily on the harmonization of data across diverse sources with varying standards, formats, and completeness (Velummailum et al., 2023). Clinical trial and real-world pharmacovigilance data often originate from heterogeneous environments, complicating direct linkage. Without rigorous data preprocessing and standardization, tokenization can generate mismatches or fragmentations, threatening data integrity and skewing pharmacovigilance outcomes (Walters et al., 2025). Incorporating privacy-preserving record linkage (PPRL) mechanisms alongside tokenization further ensures secure integration of datasets without exposing sensitive patient identifiers. However, weak encryption or lax access controls risk breaching patient confidentiality, undermining trust in the entire pharmacovigilance data ecosystem.

In health economics and safety studies, linking clinical trial and pharmacovigilance data to economic datasets is pivotal for accurate cost-effectiveness and safety analyses. Inaccuracies in tokenization or linkage processes can yield incomplete or biased datasets, obscuring critical cost drivers or patient-level treatment responses. This threatens the reliability of economic evaluations that inform reimbursement and regulatory decisions, potentially affecting trial feasibility and therapeutic innovation (Li et al., 2024).

Merging primary clinical trial and pharmacovigilance datasets with secondary sources—such as claims, social determinants of health (SDOH), genomic, and mortality data—introduces additional complexities. The distinction between primary and secondary data depends on collection context. Primary data refers to information collected for the specific study at hand (e.g., clinical trial data), whereas secondary data (e.g., claims or SDOH) is repurposed for analysis. Depending on how pharmacovigilance data is generated, it may fall into either category (Gliklich et al., 2014). These datasets often differ in structure and standards, necessitating robust preprocessing and referential matching algorithms to ensure consistent token mapping across all sources (Eckrote et al., 2024). Failure to properly align these data can degrade the accuracy of pharmacovigilance real-world evidence (RWE) and impede valid interpretation. Furthermore, enriching tokenized datasets with external data must be carefully managed within regulatory frameworks to prevent inadvertent exposure of protected health information (Office for Civil Rights, 2023).

A critical challenge involves enabling controlled, secure re-identification for pharmacovigilance activities such as safety signal validation and adverse event follow-up. Tokenization frameworks in pharmacoepidemiology often include tightly regulated re-identification protocols managed by neutral data custodians. These custodians maintain encrypted mappings between tokens and original identifiers within secure environments, allowing re-identification only under ethically approved, regulatorily compliant conditions (ENCePP, 2020). This approach balances stringent privacy protection with the operational necessity of patient-level follow-up in pharmacovigilance, supported by access controls, audit trails, and regulatory oversight.

Although tokenization is gaining adoption in regulatory-grade data linkage, explicit examples in published pharmacoepidemiology studies are limited due to commercial and privacy constraints. The following three applied scenarios illustrate how tokenization enables privacy-preserving linkage for post-market safety research and real-world evidence (RWE) generation:

Scenario 1: Linking Claims and EHRs to Detect Adverse Events Post-Approval.

After FDA approval of a new anticoagulant, a manufacturer initiates post-marketing surveillance. Using referential tokenization, patient-level claims data (hospitalizations, diagnoses, procedures) are linked to EHRs (lab values, medication reconciliation, bleeding risk scores). This enables early detection of adverse drug reactions (e.g., GI bleeding) that may not be fully captured in claims alone fulfilling a regulatory risk minimization requirement (Eckrote et al., 2024).

Tokenization Use: Demographic fields (e.g., full DOB, sex, ZIP code) are cryptographically hashed and tokenized by a third-party tokenization network.

Scenario 2: Linking Registry and Claims Data for Long-Term Drug Safety Monitoring.

A national rheumatoid arthritis (RA) registry collects longitudinal clinical data on disease activity, biologic use, and side effects. Researchers seek to evaluate long-term malignancy risk associated with a specific TNF inhibitor informing black-box warning updates (D’Andrea et al., 2024).

Tokenization Use: Patients in the registry are tokenized using referential methods. Claims data from Medicare and commercial payers are then linked to capture incident cancer diagnoses, procedures, and prescription fills.

Scenario 3: Linking Clinical Trial Participants to Claims for Safety Follow-up.

A pivotal oncology trial identifies a rare cardiovascular signal in interim analysis. To assess whether this signal emerges in broader populations, the sponsor uses tokenization to link trial participants to U.S. claims data post-trial enabling regulatory submission of updated safety data (DIA RWE, 2023).

Tokenization Use: At consent, participant demographics are tokenized. Tokens are matched with commercial claims data over a 2-year period post-trial.

Outcome: Analysis identifies real-world incidence rates of cardiac events, enabling regulatory submission of updated safety data and refined risk communication in product labeling.

Table 3 summarizes pharmacoepidemiology-specific scenarios underscore tokenization’s pivotal role in enabling safety signal detection, longitudinal outcomes research, and regulatory-grade data integration—without compromising patient privacy. As tokenized infrastructures mature, their adoption will expand across global post-marketing surveillance networks and distributed data networks.

In conclusion, tokenization serves as an essential enabler for privacy-preserving data integration in clinical research and pharmacovigilance. By securely replacing sensitive patient identifiers with irreversible tokens, tokenization enables comprehensive analysis of complex, multi-source datasets—ranging from electronic health records (EHRs) and claims to genomic and patient-reported outcomes—while maintaining patient confidentiality throughout the clinical trial and post-market pharmacovigilance lifecycle.

Referential tokenization, in particular, supports scalable, high-precision linkage of disparate datasets, ensuring compliance with evolving global privacy frameworks such as GDPR and the European Health Data Space (EHDS). This approach facilitates the construction of richer, longitudinal patient profiles essential for safety monitoring, benefit-risk assessment, and health equity research, all while minimizing the risk of data exposure through adherence to de-identification and pseudonymization standards.

To fully realize tokenization’s transformative potential in pharmacovigilance, key technical challenges must be addressed. These include ensuring data integrity through rigorous standardization and harmonization, managing token lifecycles effectively, maintaining linkage accuracy to avoid both over-linking and under-linking, and implementing controlled re-identification mechanisms for authorized pharmacovigilance follow-up.

Additionally, enriching tokenized datasets with secondary sources such as claims, social determinants of health (SDOH), and mortality data offers valuable clinical insights but demands strict governance to uphold data alignment and regulatory compliance.

Empirical evidence underscores tokenization’s impact, as demonstrated in applied clinical trial settings with secure linkage of real-world data achieving high precision, enabling robust longitudinal analyses and international collaboration under stringent privacy constraints (D’Andrea et al., 2024). As clinical research and pharmacovigilance increasingly rely on interoperable real-world data, tokenization will remain central to unlocking the full analytic value of healthcare datasets while safeguarding patient privacy.

Future directions should focus on refining tokenization algorithms, establishing international standards for tokenized data reporting, and advancing trusted data custodian models that balance patient confidentiality with investigational imperatives. These efforts will underpin the continued evolution of clinical research toward resilient, patient-centric paradigms that harmonize privacy preservation with data-driven innovation and regulatory rigor.